Skip to main content
Top
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study

Authors: Rahul Roychoudhuri, David Robinson, Venkata Putcha, Jack Cuzick, Sarah Darby, Henrik Møller

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

Breast radiotherapy as practised in the 1970s and 1980s resulted in significant myocardial exposure, and this was higher when the left breast was treated. It has been proposed that this difference might result in greater cardiovascular mortality following irradiation of the left breast when compared with the right.

Methods

All cases of female breast cancer diagnosed between 1971 and 1988 and recorded on the Thames Cancer Registry database were followed up to the end of 2003 to identify cases who had died from ischaemic heart disease (IHD) or any cardiovascular disease (CVD). A proportional hazards regression analysis was performed, stratified by time since diagnosis, using as the baseline group those women with right-sided disease who did not receive radiotherapy, and adjusting for age at diagnosis.

Results

A total of 20,871 women with breast cancer were included in the analysis, of which 51% had left-sided disease. Mortality at 15+ years after diagnosis was increased in recipients of left-breast radiotherapy compared to non-irradiated women with right-sided breast cancer, both for IHD (hazard ratio 1.59; 95% confidence interval 1.21–2.08; p = 0.001) and all CVD (hazard ratio 1.27; 95% confidence interval 1.07–1.51; p = 0.006). When irradiated women with left-sided breast cancer were compared with irradiated women with right-sided breast cancer, cardiovascular mortality at 15+ years after diagnosis was raised by around 25% (IHD: hazard ratio 1.23; 95% confidence interval 0.95–1.60; p = 0.114; CVD: hazard ratio 1.25; 95% confidence interval 1.05–1.49; p = 0.014).

Conclusion

We have found an elevation in cardiovascular mortality more than 15 years after breast radiotherapy in women diagnosed with breast cancer between 1971 and 1988. The risk was greater following irradiation of the left breast compared with the right. This confirms that radiotherapy as practised in the 1970s and 1980s has resulted in significant long-term cardiac toxicity. In absolute terms, the increase in cardiovascular mortality induced by radiotherapy may be substantial, as these mortality events are relatively common.
Literature
1.
go back to reference Shimizu Y, Pierce DA, Preston DL, Mabuchi K: Studies of the mortality of atomic bomb survivors: non-cancer mortality 1950–1990. Radiat Res. 1999, 152: 374-389. 10.2307/3580222. (Report 12, part II)CrossRefPubMed Shimizu Y, Pierce DA, Preston DL, Mabuchi K: Studies of the mortality of atomic bomb survivors: non-cancer mortality 1950–1990. Radiat Res. 1999, 152: 374-389. 10.2307/3580222. (Report 12, part II)CrossRefPubMed
2.
go back to reference Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 366: 2087-2106.CrossRef Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 366: 2087-2106.CrossRef
3.
go back to reference Darby SC, McGale P, Taylor CW, Peto R: Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol. 2005, 6: 557-565. 10.1016/S1470-2045(05)70251-5.CrossRefPubMed Darby SC, McGale P, Taylor CW, Peto R: Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol. 2005, 6: 557-565. 10.1016/S1470-2045(05)70251-5.CrossRefPubMed
4.
go back to reference Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A: Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90000 Swedish women. BMJ. 2003, 326: 256-257. 10.1136/bmj.326.7383.256.CrossRefPubMedPubMedCentral Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A: Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90000 Swedish women. BMJ. 2003, 326: 256-257. 10.1136/bmj.326.7383.256.CrossRefPubMedPubMedCentral
5.
go back to reference Department of the Environment Transport and the Regions: Indices of Deprivation 2000: Regeneration Research Summary No 31. 2000, London: Stationery Office Department of the Environment Transport and the Regions: Indices of Deprivation 2000: Regeneration Research Summary No 31. 2000, London: Stationery Office
6.
go back to reference Rutqvist LE, Johansson H: Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer. 1990, 61: 866-868.CrossRefPubMedPubMedCentral Rutqvist LE, Johansson H: Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer. 1990, 61: 866-868.CrossRefPubMedPubMedCentral
7.
go back to reference Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, Peto R, Baum M, Fisher B, Host H, Lythgoe J, Ribeiro G, Scheurlen H: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994, 12: 447-453.PubMed Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, Peto R, Baum M, Fisher B, Host H, Lythgoe J, Ribeiro G, Scheurlen H: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994, 12: 447-453.PubMed
8.
go back to reference Hooning MJ, Aleman BMP, van Rosmalen AJM, Kuenen MA, Klijn JGM, van Leeuwen FE: Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys. 2006, 64: 1081-1091. 10.1016/j.ijrobp.2005.10.022.CrossRefPubMed Hooning MJ, Aleman BMP, van Rosmalen AJM, Kuenen MA, Klijn JGM, van Leeuwen FE: Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys. 2006, 64: 1081-1091. 10.1016/j.ijrobp.2005.10.022.CrossRefPubMed
11.
go back to reference Giordano SH, Kuo Y-F, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005, 97: 419-424.CrossRefPubMedPubMedCentral Giordano SH, Kuo Y-F, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005, 97: 419-424.CrossRefPubMedPubMedCentral
12.
go back to reference Violet JA, Harmer C: Breast cancer: improving outcome following adjuvant radiotherapy. Br J Radiol. 2004, 77: 811-820. 10.1259/bjr/44576710.CrossRefPubMed Violet JA, Harmer C: Breast cancer: improving outcome following adjuvant radiotherapy. Br J Radiol. 2004, 77: 811-820. 10.1259/bjr/44576710.CrossRefPubMed
Metadata
Title
Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study
Authors
Rahul Roychoudhuri
David Robinson
Venkata Putcha
Jack Cuzick
Sarah Darby
Henrik Møller
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-9

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine